Skip to main content

Table 1 Baseline characteristics

From: Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab–paclitaxel or FOLFIRINOX: A post–hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study)

 

n=318

Age (years), n (%)

 

<60

93 (29)

60 – 70

137 (43)

>70

88 (28)

Sex (M/F), n (%)

196/122 (62/38)

ECOG PS, n (%)

 

0

204 (64)

1

96 (30)

2 or more

17 (5)

Body mass index (kg/m2), n (%)

 

<22

198 (62)

≥22

120 (38)

Tumor resection, n (%)

44 (14)

Pancreatic tumor location, n (%)

 

Head

165 (52)

Body

94 (30)

Tail

59 (19)

Tumor size (mm), n (%)

32 (1 – 98)

<20

41 (13)

20 – 40

181 (57)

>40

96 (30)

Histology, n (%)

 

Adenocarcinoma

271 (85)

Others

47 (15)

Unknown

37 (12)

Site of metastatic disease, n (%)

 

Liver

154 (48)

Peritoneum

62 (19)

Lung

39 (12)

Number of metastatic sites, n (%)

 

≥2

97 (31)

Ascites, n (%)

62 (19)

Albumin (g/dL), n (%)

 

>4

32 (10)

3 – 4

181 (57)

<3

105 (33)

LDH (U/L), n (%)

 

<240

269 (85)

240 – 360

105 (33)

>360

8 (3)

CRP (mg/dL), n (%)

 

<0.3

158 (50)

0.3 – 3.0

117 (37)

>3.0

43 (14)

CA19–9 (U/mL), n (%)

 

<37

76 (24)

37 – 370

72 (23)

>370

170 (53)

AJCC TNM stage, n (%)

 

III

63 (20)

IV

255 (80)

First line regimen, n (%)

 

GnP

200 (63)

FFX

118 (37)

  1. Abbreviations: ECOG PS Eastern Cooperative Oncology Group performance status, LDH lactate dehydrogenase, CRP C–reactive protein, CA19–9 carbohydrate antigen 19–9, AJCC American Joint Committee on Cancer, GnP gemcitabine plus nab–paclitaxel, FFX FOLFIRINOX